G. Marek

发表

Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release

G. Aghajanian, G. Marek, 1999, Brain Research.

Serotonin model of schizophrenia: emerging role of glutamate mechanisms

G. Aghajanian, G. Marek, Gerard J Marek, 2000, Brain Research Reviews.

Awake Rat Pharmacological Magnetic Resonance Imaging as a Translational Pharmacodynamic Biomarker: Metabotropic Glutamate 2/3 Agonist Modulation of Ketamine-Induced Blood Oxygenation Level Dependence Signals

Min Zhang, Jaymin Upadhyay, Min Zhang, 2011, Journal of Pharmacology and Experimental Therapeutics.

Default-Mode-Like Network Activation in Awake Rodents

Younglim Lee, G. Marek, M. Day, 2011, PloS one.

Antidepressant-like effects of trazodone on a behavioral screen are mediated by trazodone, not the metabolite m-chlorophenylpiperazine.

G. Marek, L. Seiden, A. Li, 1990, European journal of pharmacology.

N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide (THIIC), a Novel Metabotropic Glutamate 2 Potentiator with Potential Anxiolytic/Antidepressant Properties: In Vivo Profiling Suggests a Link between Behavioral and Central Nervous System Neu

G. Marek, K. Perry, J. Witkin, 2011, Journal of Pharmacology and Experimental Therapeutics.

A mGlu2/3 receptor agonist for schizopherenia

G. Marek, 2008 .

Pharmacological and Pharmacokinetic Properties of a Structurally-Novel , Potent , Selective mGlu 2 / 3 Receptor Agonist : In Vitro Characterization of LY 404039

G. Marek, E. Nisenbaum, D. McKinzie, 2007 .

Pharmacological and Pharmacokinetic Properties of a Structurally Novel, Potent, and Selective Metabotropic Glutamate 2/3 Receptor Agonist: In Vitro Characterization of Agonist (–)-(1R,4S,5S,6S)-4-Amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic Acid (LY404039)

G. Marek, E. Nisenbaum, D. McKinzie, 2007, Journal of Pharmacology and Experimental Therapeutics.

Developing Serotonergic Antidepressants Acting on More Than the Serotonin Transporter

G. Marek, 2017 .

Neurotoxicity in Dopamine and 5‐Hydroxytryptamine Terminal Fields: A Regional Analysis in Nigrostriatal and Mesolimbic Projections

G. Marek, L. Seiden, D. Commins, 1988, Annals of the New York Academy of Sciences.

Heterocomplex formation of 5-HT2A-mGlu2 and its relevance for cellular signaling cascades

G. Marek, G. Terstappen, A. Meyer, 2012, Neuropharmacology.

Interactions of Hallucinogens with the Glutamatergic System: Permissive Network Effects Mediated Through Cortical Layer V Pyramidal Neurons.

G. Marek, 2018, Current topics in behavioral neurosciences.

The two faces of the pharmacological interaction of mGlu2 and 5-HT2A – Relevance of receptor heterocomplexes and interaction through functional brain pathways

G. Marek, M. Mezler, H. K. Delille, 2013, Neuropharmacology.

LY-2140023, a prodrug of the group II metabotropic glutamate receptor agonist LY-404039 for the potential treatment of schizophrenia.

G. Marek, M. Mezler, L. Gault, 2010, Current opinion in investigational drugs.

Dopamine uptake inhibitors block long-term neurotoxic effects of methamphetamine upon dopaminergic neurons

G. Marek, L. Seiden, G. Vosmer, 1990, Brain Research.

Neurological Disease and Suicidal Behavior

G. Marek, T. Hudzik, 2014 .

APOE-ɛ4 Carrier Status and Donepezil Response in Patients with Alzheimer’s Disease

J. Waring, G. Marek, S. Dutta, 2015, Journal of Alzheimer's disease : JAD.

Effect of Ketoconazole on the Pharmacokinetics of the 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor ABT-384 and Its Two Active Metabolites in Healthy Volunteers: Population Analysis of Data from a Drug-Drug Interaction Study

G. Marek, S. Dutta, G. An, 2013, Drug Metabolism and Disposition.

A comparison of trazodone and fluoxetine: implications for a serotonergic mechanis of antidepressant action

C. McDougle, G. Marek, L. Seiden, 2005, Psychopharmacology.

Development of the 2nd generation neurokinin-1 receptor antagonist LY686017 for social anxiety disorder

G. Marek, S. Iyengar, F. Vandenhende, 2010, European Neuropsychopharmacology.

Metabotropic glutamate 2/3 receptors as drug targets.

G. Marek, 2004, Current opinion in pharmacology.

The 5-Hydroxytryptamine 2A Receptor Antagonist R -( (cid:1) )- (cid:1) -(2,3-Dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl-4-piperidinemethanol(M100907)AttenuatesImpulsivity after Both Drug-Induced Disruption (Dizocilpine) and Enhancement (Antidepressant Drugs) of Differential-Reinforcement-of-Low-Rat

G. Marek, S. Chaney, J. Catlow, 2008 .

Preclinical pharmacology of mGlu2/3 receptor agonists: novel agents for schizophrenia?

G. Marek, D. Dd, 2002, Current drug targets. CNS and neurological disorders.

Safety, Pharmacokinetics, and Pharmacodynamics of ASP3662, a Novel 11β‐Hydroxysteroid Dehydrogenase Type 1 Inhibitor, in Healthy Young and Elderly Subjects

G. Marek, W. Krauwinkel, M. Walzer, 2019, Clinical and translational science.

Peripheral and central nervous system inhibition of 11β-hydroxysteroid dehydrogenase type 1 in man by the novel inhibitor ABT-384

G. Marek, D. Barnes, L. Ereshefsky, 2013, Translational Psychiatry.

Population pharmacokinetics of the 11β‐hydroxysteroid dehydrogenase type 1 inhibitor ABT‐384 in healthy volunteers following single and multiple dose regimens

G. Marek, S. Dutta, G. An, 2014, Biopharmaceutics & drug disposition.

Single‐ and Multiple‐Dose Safety, Tolerability, and Pharmacokinetic Profiles of ASP8062: Results From 2 Phase 1 Studies

G. Marek, M. Nagata, M. Walzer, 2020, Clinical pharmacology in drug development.

Metabotropic glutamate receptors in the control of mood disorders.

G. Marek, J. Witkin, D. Schoepp, 2007, CNS & neurological disorders drug targets.

Comparison of the effects of mianserin and its enantiomers and metabolites on a behavioral screen for antidepressant activity

G. Marek, L. Seiden, Timothy H. Hand, 2005, Psychopharmacology.

D3 receptor target engagement in humans with ABT-925 using [11C](+)-PHNO PET.

G. Marek, M. Day, G. Fox, 2010, The international journal of neuropsychopharmacology.

Alpha 1B-adrenoceptor-mediated excitation of piriform cortical interneurons.

G. Aghajanian, G. Marek, 1996, European journal of pharmacology.

The effects of monoamine uptake inhibitors and methamphetamine on neostriatal 6-hydroxydopamine (6-OHDA) formation, short-term monoamine depletions and locomotor activity in the rat

G. Marek, L. Seiden, G. Vosmer, 1990, Brain Research.

Serotonin–Glutamate Interactions: A New Target for Antipsychotic Drugs

G. Aghajanian, G. Marek, 1999, Neuropsychopharmacology.

Developing predictive CSF biomarkers-a challenge critical to success in Alzheimer's disease and neuropsychiatric translational medicine.

G. Marek, D. Flood, Michael Williams, 2011, Biochemical pharmacology.

Efficacy and Safety of ASP0819 in Patients with Fibromyalgia: Results of a Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial

G. Marek, M. B. Blauwet, M. Walzer, 2020, Journal of pain research.

The Utility of Impulsive Bias and Altered Decision Making as Predictors of Drug Efficacy and Target Selection: Rethinking Behavioral Screening for Antidepressant Drugs

G. Marek, M. Day, T. Hudzik, 2016, The Journal of Pharmacology and Experimental Therapeutics.

Adenosine preferentially suppresses serotonin2A receptor-enhanced excitatory postsynaptic currents in layer V neurons of the rat medial prefrontal cortex

G. Aghajanian, G. Marek, G. Stutzmann, 2001, Neuroscience.

5-HT2A Receptor-Mediated Regulation of Brain-Derived Neurotrophic Factor mRNA in the Hippocampus and the Neocortex

G. Aghajanian, G. Marek, R. Duman, 1997, The Journal of Neuroscience.

Orexin 2 Receptor Antagonists from Prefrontal Cortical Circuitry to Rodent Behavioral Screens

G. Marek, S. Chaney, M. Benvenga, 2019, Antidepressants - Preclinical, Clinical and Translational Aspects.

Serotonin Induces Excitatory Postsynaptic Potentials in Apical Dendrites of Neocortical Pyramidal Cells

G. Aghajanian, G. Marek, G. K AGHAJANIAN, 1997, Neuropharmacology.

The impact of genetics on future drug discovery in schizophrenia

G. Marek, M. Matsumoto, H. Yamada, 2017, Expert opinion on drug discovery.

Glutamatergic (N-Methyl-d-aspartate Receptor) Hypofrontality in Schizophrenia: Too Little Juice or a Miswired Brain?

Younglim Lee, H. Schoemaker, G. Marek, 2010, Molecular Pharmacology.

A phase 1b study to investigate the potential interactions between ASP8062 and buprenorphine/naloxone in patients with opioid use disorder

G. Marek, M. Walzer, P. Blahunka, 2023, Journal of psychopharmacology.

The Selective 5-HT2A Receptor Antagonist M100907 Enhances Antidepressant-Like Behavioral Effects of the SSRI Fluoxetine

G. Marek, F. Artigas, R. Martı́n-Ruiz, 2005, Neuropsychopharmacology.

Selective inhibition of MAO-A, not MAO-B, results in antidepressant-like effects on DRL 72-s behavior

G. Marek, L. Seiden, 2004, Psychopharmacology.

Lithium Augmentation of Fluvoxamine in Autistic Disorder: A Case Report

C. McDougle, F. Volkmar, G. Marek, 1994 .

Essential Role of the fosB Gene in Molecular, Cellular, and Behavioral Actions of Chronic Electroconvulsive Seizures

M. Greenberg, G. Marek, N. Hiroi, 1998, The Journal of Neuroscience.

Electrophysiology of Serotonin Receptors

G. Marek, 2010 .

Metabotropic Glutamate 2/3 Receptor Agonists and Positive Allosteric Modulators of Metabotropic Glutamate Receptor 2 as Novel Agents for the Treatment of Schizophrenia

G. Marek, D. McKinzie, B. Kinon, 2012 .

Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex.

G. Aghajanian, G. Marek, D. Schoepp, 2000, The Journal of pharmacology and experimental therapeutics.

Synergistic Action of 5-HT2A Antagonists and Selective Serotonin Reuptake Inhibitors in Neuropsychiatric Disorders

C. McDougle, G. Marek, L. Price, 2003, Neuropsychopharmacology.

Clinical Safety, Pharmacokinetics, and Pharmacodynamics of the 11β‐Hydroxysteroid Dehydrogenase Type 1 Inhibitor ABT‐384 in Healthy Volunteers and Elderly Adults

G. Marek, S. Dutta, C. Locke, 2013, Clinical pharmacology in drug development.

Activation of adenosine1 (A1) receptors suppresses head shakes induced by a serotonergic hallucinogen in rats

G. Marek, 2009, Neuropharmacology.

Developing therapeutics for schizophrenia and other psychotic disorders

G. Marek, Kalpana M. Merchant, 2005, NeuroRX.

The 5-Hydroxytryptamine2A Receptor Antagonist R-(+)-α-(2,3-Dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl-4-piperidinemethanol (M100907) Attenuates Impulsivity after Both Drug-Induced Disruption (Dizocilpine) and Enhancement (Antidepressant Drugs) of Differential-Reinforcement-of-Low-Rate 72-s Behavior

G. Marek, S. Chaney, J. Catlow, 2008, Journal of Pharmacology and Experimental Therapeutics.

Serotonin and dopamine interactions in rodents and primates: implications for psychosis and antipsychotic drug development.

G. Marek, 2007, International review of neurobiology.

Long-term central 5-HT depletions resulting from repeated administration of MDMA enhances the effects of single administration of MDMA on schedule-controlled behavior of rats

G. Marek, L. Seiden, G. Vosmer, 1989, Pharmacology Biochemistry and Behavior.

AMPA receptor involvement in 5-hydroxytryptamine2A receptor-mediated pre-frontal cortical excitatory synaptic currents and DOI-induced head shakes

G. Marek, Ce Zhang*, 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Behavioral evidence for mu-opioid and 5-HT2A receptor interactions.

G. Marek, 2003, European journal of pharmacology.

Behavioral Evidence for Interactions between a Hallucinogenic Drug and Group II Metabotropic Glutamate Receptors

J. Gewirtz, G. Marek, 2000, Neuropsychopharmacology.

Metabotropic glutamate2/3 (mGlu2/3) receptors, schizophrenia and cognition.

G. Marek, 2010, European journal of pharmacology.

Displacement of Serotonin and Dopamine Transporters by Venlafaxine Extended Release Capsule at Steady State: A [123I]2β-Carbomethoxy-3β-(4-Iodophenyl)-Tropane Single Photon Emission Computed Tomography Imaging Study

G. Marek, J. Seibyl, K. Marek, 2007, Journal of clinical psychopharmacology.

Heterocomplex formation of 5-HT2A-mGlu2 and its relevance for cellular signaling cascades

G. Marek, G. Terstappen, M. Mezler, 2012, Neuropharmacology.

Antidepressant effects assessed using behavior maintained under a differential-reinforcement-of-low-rate (DRL) operant schedule

G. Marek, L. Seiden, J. O'Donnell, 2005, Neuroscience & Biobehavioral Reviews.

5-HT2A receptor or alpha1-adrenoceptor activation induces excitatory postsynaptic currents in layer V pyramidal cells of the medial prefrontal cortex.

G. Aghajanian, G. Marek, G K Aghajanian, 1999, European journal of pharmacology.

LSD and the phenethylamine hallucinogen DOI are potent partial agonists at 5-HT2A receptors on interneurons in rat piriform cortex.

G. Aghajanian, G. Marek, 1996, The Journal of pharmacology and experimental therapeutics.

Efficacy and safety evaluation of HSD-1 inhibitor ABT-384 in Alzheimer's disease

G. Marek, R. Lenz, Wuyan Zhang, 2014, Alzheimer's & Dementia.

Regulation of rat cortical 5-hydroxytryptamine2A receptor-mediated electrophysiological responses by repeated daily treatment with electroconvulsive shock or imipramine

G. Marek, 2008, European Neuropsychopharmacology.

A phase 1 randomized, placebo-controlled study to investigate potential interactions between ASP8062, a positive allosteric modulator of the GABAB receptor, and morphine in recreational opioid users

G. Marek, M. B. Blauwet, M. Walzer, 2023, Journal of psychopharmacology.

The mGlu2/3 Receptor Agonists LY354740 and LY379268 Differentially Regulate Restraint-Stress-Induced Expression of c-Fos in Rat Cerebral Cortex

G. Marek, J. Mikkelsen, K. Merchant, 2013, Neuroscience journal.

Buspirone, gepirone, ipsapirone, and zalospirone have distinct effects on the differential-reinforcement-of-low-rate 72-s schedule when compared with 5-HTP and diazepam

G. Marek, J. Richards, L. Seiden, 1994, Psychopharmacology.

A randomized phase 1 single-dose polysomnography study of ASP8062, a GABAB receptor positive allosteric modulator

G. Marek, G. Zammit, M. Walzer, 2021, Psychopharmacology.

The electrophysiology of prefrontal serotonin systems: therapeutic implications for mood and psychosis

G. Aghajanian, G. Marek, Gerard J Marek, 1998, Biological Psychiatry.

Indoleamine and the phenethylamine hallucinogens: mechanisms of psychotomimetic action.

G. Aghajanian, G. Marek, 1998, Drug and alcohol dependence.

Translational Approaches for Antidepressant Drug Development

G. Marek, 2019, Translational Medicine in CNS Drug Development.

Cortical 5-hydroxytryptamine2A-receptor mediated excitatory synaptic currents in the rat following repeated daily fluoxetine administration

G. Marek, 2008, Neuroscience Letters.

Pargyline increases 6-hydroxydopamine levels in the neostriatum of methamphetamine-treated rats

G. Marek, L. Seiden, G. Vosmer, 1990, Pharmacology Biochemistry and Behavior.

A Novel Approach to the Identification of Psychiatric Drugs: Serotonin-Glutamate Interactions in the Prefrontal Cortex

G. Marek, 2006 .

Imaging the Enzyme 11β-Hydroxysteroid Dehydrogenase Type 1 with PET: Evaluation of the Novel Radiotracer 11C-AS2471907 in Human Brain

Yiyun Huang, G. Marek, R. Carson, 2019, The Journal of Nuclear Medicine.

Xanomeline Modulation of the Blood Oxygenation Level-Dependent Signal in Awake Rats: Development of Pharmacological Magnetic Resonance Imaging as a Translatable Pharmacodynamic Biomarker for Central Activity and Dose Selection

Scott Baker, G. Marek, M. Day, 2012, Journal of Pharmacology and Experimental Therapeutics.

Metabotropic Glutamate2 Receptors Play a Key Role in Modulating Head Twitches Induced by a Serotonergic Hallucinogen in Mice

G. Marek, M. Baez, S. Chaney, 2018, Front. Pharmacol..

A major role for thalamocortical afferents in serotonergic hallucinogen receptor function in the rat neocortex

J. Gewirtz, G. Marek, D. Schoepp, 2001, Neuroscience.

CNS distribution of metabotropic glutamate 2 and 3 receptors: Transgenic mice and [3H]LY459477 autoradiography

G. Marek, D. Schoepp, D. Calligaro, 2013, Neuropharmacology.

Group III Metabotropic Glutamate Receptor Agonists Selectively Suppress Excitatory Synaptic Currents in the Rat Prefrontal Cortex Induced by 5-Hydroxytryptamine2A Receptor Activation

G. Marek, Ce Zhang*, 2007, Journal of Pharmacology and Experimental Therapeutics.

Metabotropic Glutamate Receptor Agonists Selectively Suppress Excitatory Synaptic Currents in the Rat Prefrontal Cortex Induced by 5-Hydroxytryptamine 2 A Receptor Activation

G. Marek, Ce Zhang*, 2006 .

Pharmacokinetics of ASP4345 from Single Ascending-Dose and Multiple Ascending-Dose Phase I Studies

G. Marek, Lauren Benner, T. Uz, 2020, Clinical Pharmacokinetics.

Cortical influences of serotonin and glutamate on layer V pyramidal neurons.

G. Marek, D. Schoepp, 2021, Progress in brain research.

Phase 1 randomized study on the safety, tolerability, and pharmacodynamic cognitive and electrophysiological effects of a dopamine D1 receptor positive allosteric modulator in patients with schizophrenia

G. Marek, P. Maruff, G. Light, 2020, Neuropsychopharmacology.

In Vitro and in Vivo Evidence for a Lack of Interaction with Dopamine D2 Receptors by the Metabotropic Glutamate 2/3 Receptor Agonists 1S,2S,5R,6S-2-Aminobicyclo[3.1.0]hexane-2,6-bicaroxylate Monohydrate (LY354740) and (−)-2-Oxa-4-aminobicyclo[3.1.0] Hexane-4,6-dicarboxylic Acid (LY379268)

G. Marek, K. Perry, D. McKinzie, 2009, Journal of Pharmacology and Experimental Therapeutics.

Excitation of interneurons in piriform cortex by 5-hydroxytryptamine: blockade by MDL 100,907, a highly selective 5-HT2A receptor antagonist.

G. Aghajanian, G. Marek, 1994, European journal of pharmacology.

5-Hydroxytryptamine-induced excitatory postsynaptic currents in neocortical layer V pyramidal cells: suppression by μ-opiate receptor activation

G. Aghajanian, G. Marek, 1998, Neuroscience.

Selective 5-hydroxytryptamine2 antagonists have antidepressant-like effects on differential-reinforcement-of-low-rate 72-second schedule.

G. Marek, L. Seiden, A. Li, 1989, The Journal of pharmacology and experimental therapeutics.

Effects of selective 5-hydroxytryptamine-2 and nonselective 5-hydroxytryptamine antagonists on the differential-reinforcement-of-low-rate 72-second schedule.

G. Marek, L. Seiden, 1988, The Journal of pharmacology and experimental therapeutics.

Behavioral evidence for A-opioid and 5-HT 2A receptor interactions

G. Marek, 2003 .

Extending the Specificity of DRL 72-s Behavior for Screening Antidepressant-Like Effects of Glutamatergic Clinically Validated Anxiolytic or Antidepressant Drugs in Rats

G. Marek, Allyson A Salek, 2020, The Journal of Pharmacology and Experimental Therapeutics.

Effects of a Positive Allosteric Modulator of Group II Metabotropic Glutamate Receptors, LY487379, on Cognitive Flexibility and Impulsive-Like Responding in Rats

H. Schoemaker, G. Marek, P. Popik, 2010, Journal of Pharmacology and Experimental Therapeutics.

Activation of Adenosine1 Receptors Induces Antidepressant-Like, Anti-Impulsive Effects on Differential Reinforcement of Low-Rate 72-s Behavior in Rats

G. Marek, 2012, Journal of Pharmacology and Experimental Therapeutics.

5-Hydroxytryptamine2A (5-HT2A) receptor regulation in rat prefrontal cortex: Interaction of a phenethylamine hallucinogen and the metabotropic glutamate2/3 receptor agonist LY354740

G. Marek, D. Schoepp, R. Wright, 2006, Neuroscience Letters.

Activation of metabotropic glutamate 5 (mGlu5) receptors induces spontaneous excitatory synaptic currents in layer V pyramidal cells of the rat prefrontal cortex

G. Marek, Ce Zhang*, 2008, Neuroscience Letters.

β2-Adrenergic Receptor Activation Suppresses the Rat Phenethylamine Hallucinogen-Induced Head Twitch Response: Hallucinogen-Induced Excitatory Post-synaptic Potentials as a Potential Substrate

G. Marek, B. Ramos, 2018, Front. Pharmacol..

The mGlu2/3 receptor agonist LY354740 suppresses immobilization stress-induced increase in rat prefrontal cortical BDNF mRNA expression

Younglim Lee, G. Marek, R. Duman, 2006, Neuroscience Letters.

Modulation of DOI-induced increases in cortical BDNF expression by group II mGlu receptors

J. Gewirtz, G. Marek, R. Duman, 2002, Pharmacology Biochemistry and Behavior.

Activation of Adenosine 1 Receptors Induces Antidepressant-Like , Anti-Impulsive Effects on Differential Reinforcement of Low-Rate 72s Behavior in Rats

G. Marek, 2012 .

A Novel Approach to the Identification of Psychiatric Drugs: Serotonin-Glutamate Interactions in the Prefrontal Cortex

G. Marek, 2006 .

Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments

G F Mason, G. Marek, G. Marek, 2002, Molecular Psychiatry.

A phase 1 study to assess potential interaction between ASP8062 and alcohol in healthy adult subjects

G. Marek, P. Maruff, M. B. Blauwet, 2022, Journal of psychopharmacology.

Evidence for involvement of 5-hydroxytryptamine1 receptors in antidepressant-like drug effects on differential-reinforcement-of-low-rate 72-second behavior.

G. Marek, L. Seiden, A. Li, 1989, The Journal of pharmacology and experimental therapeutics.

Glutamate and Schizophrenia: Pathophysiology and Therapeutics

G. Marek, 2002 .

LY3 54740: A Systemically Active mGlu2/mGlu3 Receptor Agonist

G. Marek, B. Moghaddam, D. Schoepp, 2006 .

LY 354740 : A Systemically Active mGlu 2 / mGlu 3 Receptor Agonist

G. Aghajanian, G. Marek, B. Moghaddam, 1999 .

Protein kinase C inhibitors enhance the 5‐HT2A receptor‐mediated excitatory effects of serotonin on interneurons in rat piriform cortex

G. Aghajanian, G. Marek, 1995, Synapse.

Developing predictive CSF biomarkers-a challenge critical to success in Alzheimer's disease and neuropsychiatric translational medicine.

G. Marek, D. Flood, Michael Williams, 2011, Biochemical pharmacology.

Translating Pharmacology into Therapeutics to Fight the Opioid Crisis

G. Marek, K. Cunningham, K. Rasmussen, 2019, The Journal of Pharmacology and Experimental Therapeutics.

Effects of caffeine and PD 116,600 on the differential-reinforcement-of-low rate 72-S (DRL 72-S) schedule of reinforcement

G. Marek, J. Richards, T. Heffner, 1993, Pharmacology Biochemistry and Behavior.